High relative risk of recurrence for stage II cancers with specific criteria, treated mostly with CAPOX. Three-month treatment shows non-inferiority in terms of recurrence-free survival compared to six-month treatment, with chemotherapy type playing a determining role. Tolerance is significantly better with the shorter treatment duration.